tetano
Editor, Senior Moderator
Transpl Infect Dis
. 2021 May 24;e13646.
doi: 10.1111/tid.13646. Online ahead of print.
Development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients after symptomatic COVID-19
Divya Bajpai[SUP] 1 [/SUP], Deepal Shah[SUP] 2 [/SUP], Sreyashi Bose[SUP] 1 [/SUP], Satarupa Deb[SUP] 1 [/SUP], Chintan Gandhi[SUP] 1 [/SUP], Tulsi Modi[SUP] 1 [/SUP], Nikhil Rao[SUP] 1 [/SUP], Kruteesh Kumar[SUP] 1 [/SUP], Nikhil Saxena[SUP] 1 [/SUP], Abhinav Katyal[SUP] 1 [/SUP], Ankita Patil[SUP] 1 [/SUP], Sayali Thakare[SUP] 1 [/SUP], Atim E Pajai[SUP] 1 [/SUP], Gita Nataraj[SUP] 2 [/SUP], Tukaram E Jamale[SUP] 1 [/SUP]
Affiliations
Abstract
The development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients (KTRs) is not clear. Though seroconversion has been documented[SUP]1[/SUP] , the persistence of this response with time is not established. We longitudinally studied the presence of anti-SARS-CoV-2 IgG antibodies in KTRs after symptomatic coronavirus disease-2019 (COVID-19). Forty-seven patients with a positive SARS-CoV-2 RTPCR between May 2020 and March 2021 were followed up in the transplant clinic for 5.55 ± 2.32 months. Sera was initially tested at day 15 from diagnosis for the presence of anti-SARS-CoV-2 total IgG antibodies using COVID KAWACH IgG MICROLISA (J. Mitra Pvt. Ltd; approved by the Indian Council of Medical Research[SUP]2[/SUP] ). It is a qualitative assay using SARS CoV-2 virus whole-cell antigen (sensitivity = 96.33%, specificity = 100%). Patients negative on day 15, were retested until they seroconverted.
Keywords: Anti- SARS-CoV-2 antibodies; COVID-19; Kidney transplantation; immunological response.
. 2021 May 24;e13646.
doi: 10.1111/tid.13646. Online ahead of print.
Development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients after symptomatic COVID-19
Divya Bajpai[SUP] 1 [/SUP], Deepal Shah[SUP] 2 [/SUP], Sreyashi Bose[SUP] 1 [/SUP], Satarupa Deb[SUP] 1 [/SUP], Chintan Gandhi[SUP] 1 [/SUP], Tulsi Modi[SUP] 1 [/SUP], Nikhil Rao[SUP] 1 [/SUP], Kruteesh Kumar[SUP] 1 [/SUP], Nikhil Saxena[SUP] 1 [/SUP], Abhinav Katyal[SUP] 1 [/SUP], Ankita Patil[SUP] 1 [/SUP], Sayali Thakare[SUP] 1 [/SUP], Atim E Pajai[SUP] 1 [/SUP], Gita Nataraj[SUP] 2 [/SUP], Tukaram E Jamale[SUP] 1 [/SUP]
Affiliations
- PMID: 34028939
- DOI: 10.1111/tid.13646
Abstract
The development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients (KTRs) is not clear. Though seroconversion has been documented[SUP]1[/SUP] , the persistence of this response with time is not established. We longitudinally studied the presence of anti-SARS-CoV-2 IgG antibodies in KTRs after symptomatic coronavirus disease-2019 (COVID-19). Forty-seven patients with a positive SARS-CoV-2 RTPCR between May 2020 and March 2021 were followed up in the transplant clinic for 5.55 ± 2.32 months. Sera was initially tested at day 15 from diagnosis for the presence of anti-SARS-CoV-2 total IgG antibodies using COVID KAWACH IgG MICROLISA (J. Mitra Pvt. Ltd; approved by the Indian Council of Medical Research[SUP]2[/SUP] ). It is a qualitative assay using SARS CoV-2 virus whole-cell antigen (sensitivity = 96.33%, specificity = 100%). Patients negative on day 15, were retested until they seroconverted.
Keywords: Anti- SARS-CoV-2 antibodies; COVID-19; Kidney transplantation; immunological response.